Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
285
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

Luigi Gargiuloa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Luciano Ibbaa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyCorrespondence[email protected]
View further author information
,
Ruggero Cascio Ingurgioa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Piergiorgio Malagolic Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyView further author information
,
Fabrizio Amorusod Dermatology Unit, Azienda Ospedaliera di Cosenza, Cosenza, ItalyView further author information
,
Anna Balatoe Dermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyView further author information
,
Federico Bardazzif Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0001-6162-2004View further author information
ORCID Icon,
Pina Briantig Dermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, ItalyView further author information
,
Giovanna Brunassoh Dermatology Department, Galliera Hospital, Genoa, ItalyView further author information
,
Martina Burlandoi Department of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, ItalyORCID Iconhttps://orcid.org/0000-0002-4381-6718View further author information
ORCID Icon,
Anna E. Cagnij Unità Operativa Dipartimentale di Dermatologia e Venereologia, IRCCS San Gerardo, Milan, ItalyView further author information
,
Marzia Capronik Immunopathology and Rare Skin Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda Unità Sanitaria Locale Toscana Centro, University of Florence, Florence, ItalyView further author information
,
Carlo G. Carreral Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyView further author information
,
Andrea Carugnom Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy;n PhD Program in Molecular and Translational Medicine (DIMET), University of Milan-Bicocca, Milan, ItalyView further author information
,
Francesco Caudulloo Dermatology Clinic, University of Catania, Catania, ItalyView further author information
,
Aldo Cucciap Unit of Dermatology, San Donato Hospital, Arezzo, ItalyView further author information
,
Paolo Dapavoq Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyView further author information
,
Eugenia V. Di Brizzie Dermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyView further author information
,
Valentina Dinir Department of Dermatology, University of Pisa, Pisa, ItalyView further author information
,
Francesca M. Gaianic Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyView further author information
,
Paolo Gisondis University of Verona, Verona, ItalyView further author information
,
Claudio Guarnerit Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ItalyView further author information
,
Claudia Lasagniu Dermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, ItalyView further author information
,
Gaetano Licatav U.O.C. Dermatology Unit, "S. Antonio Abate" Hospital, Trapani, ItalyView further author information
,
Francesco Loconsolew Department of Dermatology, University of Bari, Bari, ItalyView further author information
,
Angelo V. Marzanol Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;x Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, ItalyView further author information
,
Matteo Megnay Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
,
Santo R. Mercurig Dermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, ItalyView further author information
,
Maria L. Musumecio Dermatology Clinic, University of Catania, Catania, ItalyView further author information
,
Diego Orsiniz UOC Clinical Dermatology, Dermatological Institute S. Gallicano, IRCCS, Rome, ItalyView further author information
,
Simone Riberoq Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyView further author information
,
Valentina Ruffo Di Calabriak Immunopathology and Rare Skin Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda Unità Sanitaria Locale Toscana Centro, University of Florence, Florence, ItalyView further author information
,
Francesca Satolliaa Unit of Dermatology, University of Parma, Parma, ItalyView further author information
,
Davide Strippoliab Dermatology Unit, ASST Lecco, Alessandro Manzoni Hospital, Lecco, ItalyView further author information
,
Massimo Travagliniac U.O.S.D. dermatologica – centro per la cura della psoriasi, Ospedale Perrino, Brindisi, ItalyView further author information
,
Emanuele Trovatoad Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, ItalyView further author information
,
Marina Venturiniae Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, ItalyView further author information
,
Leonardo Zichichiv U.O.C. Dermatology Unit, "S. Antonio Abate" Hospital, Trapani, ItalyView further author information
,
Mario Valentia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Antonio Costanzoa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
&
Alessandra Narcisia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
 show all
Article: 2350760 | Received 23 Apr 2024, Accepted 29 Apr 2024, Published online: 07 May 2024

References

  • Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315. Apr 3 doi:10.1016/S0140-6736(20)32549-6.PMID: 33812489.
  • Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535. Published 2023 Jul 12. doi:10.1002/14651858.CD011535.pub6.
  • Valenti M, Narcisi A, Pavia G, et al. What can IBD specialists learn from IL-23 trials in dermatology? J Crohns Colitis. 2022;16(Supplement_2):ii20–ii29. doi:10.1093/ecco-jcc/jjac023.
  • Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials [published correction appears in lancet. 2017 jul 15;390(10091):230]. Lancet. 2017;390(10091):276–288. doi:10.1016/S0140-6736(17)31279-5.
  • European Medicines Agency. Ilumetri (tildrakizumab): sumìmary of product characteristics. 2018 [cited 2024 February 14]. https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri.
  • Thaçi D, Gerdes S, Du Jardin KG, et al. Efficacy of tildrakizumab Across different body weights in moderate-to-severe psoriasis Over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325–2341. Oct Epub 2022 Sep 13. PMID: 36098877; PMCID: PMC9515266. doi:10.1007/s13555-022-00793-z.
  • Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023;34(1):2199108. doi:10.1080/09546634.2023.2199108.
  • Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl. 1 to No. 1):1–78. doi:10.23736/S2784-8671.21.07132-2.
  • Dapavo P, Burlando M, Guarneri C, et al. Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden. Expert Opin Biol Ther. 2024;24(3):133–138. Published online March 5 doi:10.1080/14712598.2024.2325547.
  • Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103. doi:10.1111/jdv.18594.
  • Costanzo A, Llamas-Velasco M, Fabbrocini G, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37(10):2004–2015. doi:10.1111/jdv.19229.
  • Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the spanish psoriasis group. J Eur Acad Dermatol Venereol. 2023;37(12):2517–2525. doi:10.1111/jdv.19468.
  • Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343–2354. doi:10.1007/s13555-022-00800-3.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.